Biopharma & Life Sciences

Regeneron Pharmaceuticals Executive Compensation (FY25)

Name: Regeneron Pharmaceuticals (REGN) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

REGN · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Leonard Schleifer

Median of the other named officers

$7,458,970

5 officers, excluding the chief executive

Latest say-on-pay support

June 12, 2026

Chief executive pay ratio

◇

To the median employee

Free for 3 days · no card

See how Regeneron Pharmaceuticals’s pay stands against its peers

Regeneron Pharmaceuticals's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
Where Regeneron Pharmaceuticals sits against its disclosed peer group, with custom peer reruns and governance screens
Every other company we cover, with alerts when they file

Start my free trial on REGN See the plan and pricing

No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.

Velarion Intel, $499/month, or $5,000/year, about two months free: one seat · every company we cover · 7-day refund, with dashboards, peer screens and board-ready briefs.

The Regeneron Pharmaceuticals brief, $299

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $299 for the board report; $449 for both.

Get the executive brief Get the board briefNo account needed.

Data as of November 11, 2026Latest filing (8-K): June 17, 2026

11 filings cited on this page

Method: intel.velarion.ai/methodology

If a report fails to generate we keep working until you have it. No refunds on one-time reports.

Published by Velarion Company Intelligence

Regeneron Pharmaceuticals brief$299Get the executive brief

Velarion Intel, one year, every company

305 figures on this page: 298 cited to the filing that reported them, 7 calculated from figures it prints. See the citations

What changed from fiscal 2024 to fiscal 2025

The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.

Chief executive total compensation — Leonard Schleifer: $6,823,034 → $7,280,549 (6.7% higher)

Say-on-pay support: 93.3% → 93.3% (0.0 points higher)

CEO pay ratio: 41:1 → 42:1 (2.4% higher)

Frequently asked questions

Answers drawn from the data on this page.

Who is Regeneron Pharmaceuticals' chief executive and what were they paid?

Leonard Schleifer was paid $7,280,549 in total compensation as Board co-Chair, President and Chief Executive Officer for fiscal 2025. Schleifer's total was 6.7% higher than the $6,823,034 reported for fiscal 2024.

What was Regeneron Pharmaceuticals' say-on-pay result?

For fiscal 2025, shareholders backed the say-on-pay proposal with 93.3% of votes cast for or against in favor at the meeting held June 12, 2026.

Which companies are in Regeneron Pharmaceuticals' peer group?

The disclosed peer group includes AbbVie Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., Biogen Inc. and BioMarin Pharmaceutical Inc., among others.

What is Regeneron Pharmaceuticals' chief executive pay ratio?

The disclosed chief executive pay ratio for fiscal 2025 is 42:1, against median employee compensation of $174,138.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Andrew Murphy Executive Vice President, Research	◇	—	◇	◇	◇	—	◇	◇
Daniel Van Plew Executive Vice President and General Manager, Industrial Operations and Product Supply	◇	—	◇	◇	◇	—	◇	◇
Robert Landry Former Executive Vice President, Finance and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Leonard Schleifer President and Chief Executive Officer	◇	—	—	—	◇	—	◇	◇
Marion McCourt Executive Vice President, Commercial 10	◇	—	◇	◇	◇	—	◇	◇
George Yancopoulos President and Chief Scientific Officer	◇	—	—	—	◇	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Daniel Van Plew Executive Vice President and General Manager, Industrial Operations and Product Supply	◇	—	◇	◇	◇	—	◇	◇
Andrew Murphy Executive Vice President, Research	◇	—	◇	◇	◇	—	◇	◇
Leonard Schleifer Board co-Chair, President and Chief Executive Officer	◇	—	—	—	◇	—	◇	◇
George Yancopoulos Board co-Chair, President and Chief Scientific Officer	◇	—	—	—	◇	—	◇	◇
Robert Landry Former Executive Vice President, Finance and Chief Financial Officer	◇	—	—	—	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Daniel Van Plew Executive Vice President and General Manager, Industrial Operations and Product Supply	◇	—	◇	◇	◇	—	◇	◇
Andrew Murphy Executive Vice President, Research	◇	—	◇	◇	◇	—	◇	◇
Leonard Schleifer Board co-Chair, President and Chief Executive Officer	◇	—	—	—	◇	—	◇	◇
George Yancopoulos Board co-Chair, President and Chief Scientific Officer	◇	—	—	—	◇	—	◇	◇
Christopher Fenimore Executive Vice President, Finance and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Robert Landry Former Executive Vice President, Finance and Chief Financial Officer Departed during or after this year	◇	—	—	—	—	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Daniel Van Plew Executive Vice President and General Manager, Industrial Operations and Product Supply	◇	—	◇	◇	◇	—	◇	◇
Andrew Murphy Executive Vice President, Co-Chief Scientific Officer	◇	—	◇	◇	◇	—	◇	◇
Joseph LaRosa Executive Vice President, General Counsel and Secretary	◇	◇	◇	◇	◇	—	◇	◇
Leonard Schleifer Board co-Chair, President and Chief Executive Officer	◇	—	—	—	◇	—	◇	◇
Christopher Fenimore Executive Vice President, Finance and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
George Yancopoulos Board co-Chair, President and Chief Scientific Officer	◇	—	—	—	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Andrew Murphy	RSU	◇	—	—	◇	—	—	◇
Andrew Murphy	OPTION	◇	—	—	◇	—	◇	◇
Christopher Fenimore	OPTION	◇	—	—	◇	—	◇	◇
Christopher Fenimore	RSU	◇	—	—	◇	—	—	◇
Daniel Van Plew	RSU	◇	—	—	◇	—	—	◇
Daniel Van Plew	OPTION	◇	—	—	◇	—	◇	◇
Joseph LaRosa	RSU	◇	—	—	◇	—	—	◇
Joseph LaRosa	OPTION	◇	—	—	◇	—	◇	◇

Fiscal 2022, 2023, 2024 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Andrew Murphy	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Christopher Fenimore	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Joseph LaRosa	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Andrew Murphy

Executive Vice President, Co-Chief Scientific Officer · Severance agreement

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Excise tax treatment	◇
Non-solicit period	◇
Clawback	◇

Christopher Fenimore

Executive Vice President, Finance and Chief Financial Officer · Change-in-control agreement

Benefits continuation on change in control	◇
Benefits continuation	◇
Non-solicit period	◇
Clawback	◇

Daniel Van Plew

Executive Vice President · Severance agreement

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-solicit period	◇

George Yancopoulos

Board co-Chair, President and Chief Scientific Officer · Severance agreement

Benefits continuation on change in control	◇
Benefits continuation	◇
Excise tax treatment	◇
Non-solicit period	◇

Joseph LaRosa

Executive Vice President, General Counsel and Secretary · Change-in-control agreement

Benefits continuation on change in control	◇
Benefits continuation	◇
Non-solicit period	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Christine A. Poon Lead independent director	◇	◇	◇	—	—	◇	◇
George L. Sing	◇	◇	◇	—	—	◇	◇
Michael S. Brown	◇	◇	◇	—	—	◇	◇
Arthur F. Ryan	◇	◇	◇	—	—	◇	◇
Huda Y. Zoghbi	◇	◇	◇	—	—	◇	◇
N. Anthony Coles	◇	◇	◇	—	—	◇	◇
Bonnie L. Bassler	◇	◇	◇	—	—	◇	◇
Joseph L. Goldstein	◇	◇	◇	—	—	◇	◇
Craig B. Thompson	◇	◇	◇	—	—	◇	◇
David P. Schenkein	◇	◇	◇	—	—	◇	◇
Kathryn Guarini	◇	◇	◇	—	—	◇	◇

George D. Yancopoulos and Leonard S. Schleifer served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Lead independent director premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as Stock Options (80%) and RSUs (20%).

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

AbbVie Inc. ABBV
Alnylam Pharmaceuticals, Inc. ALNY
Amgen Inc. AMGN
Biogen Inc. BIIB
BioMarin Pharmaceutical Inc. BMRN
Bristol-Myers Squibb Company BMY
Eli Lilly and Company LLY
Gilead Sciences, Inc. GILD
Incyte Corporation INCY
Merck & Co., Inc. MRK
Vertex Pharmaceuticals Incorporated VRTX

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	June 12, 2026	=	◇	◇	◇
2024	June 13, 2025	=	◇	◇	◇
2023	June 14, 2024	=	◇	◇	◇
2022	June 9, 2023	=	◇	◇	◇
2021	June 10, 2022	=	◇	◇	◇
2019	June 12, 2020	=	◇	◇	◇
2016	June 9, 2017	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Leonard Schleifer (Board co-Chair, President and Chief Executive Officer), FY2025 total compensation $7,280,549 (base salary $1,979,922) [exec_comp, SEC accession 0001308179-26-000340, filed 2026-04-24]

See a complete sample report

What this page does not include

Everything above is a fact Regeneron Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Regeneron Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $299

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $299

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $299

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

305 figures on this page: 298 cited to the filing that reported them, 7 calculated from figures it prints.

298 cited to the filing

7 calculated from the filing

Documents cited

8-K, filed June 17, 2026
0001104659-26-075127
Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitiv
DEF 14A, filed April 24, 2026
0001308179-26-000340
2025 Director Compensation · 2025 Grants of Plan-Based Awards · 2025 Summary Compensation Table · Director Compensation · and 2 more sections
8-K, filed June 18, 2025
0001104659-25-060637
Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitiv
DEF 14A, filed April 29, 2025
0001308179-25-000518
2024 Summary Compensation Table
8-K, filed June 20, 2024
0001104659-24-073372
8-K, filed June 14, 2023
0001104659-23-071187
DEF 14A, filed April 21, 2023
0001308179-23-000728
2022 Summary Compensation Table
8-K, filed June 15, 2022
0001104659-22-071446
8-K, filed June 16, 2020
0001104659-20-073794
8-K, filed June 14, 2017
0001104659-17-039157
Filing, filed February 26, 2009

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Regeneron Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/REGN (accessed 2026).

Short form: data: Velarion

The Regeneron Pharmaceuticals brief, $299

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $299 for the board report; $449 for both.

Get the executive brief Get the board briefNo account needed.

11 filings cited on this page

Method: intel.velarion.ai/methodology

If a report fails to generate we keep working until you have it. No refunds on one-time reports.

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/REGN/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Regeneron Pharmaceuticals executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Regeneron Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Peers Regeneron Pharmaceuticals discloses

The companies named in REGN's own disclosed peer group.

AbbVie Inc.Alnylam Pharmaceuticals, Inc.Amgen Inc.Biogen Inc.BioMarin Pharmaceutical Inc.Bristol-Myers Squibb Company Eli Lilly and Company Gilead Sciences, Inc.Incyte Corporation Merck & Co., Inc.Vertex Pharmaceuticals Incorporated

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}